Efficacy of dexamethasone and N-acetylcysteine combination in preventing post-embolization syndrome after transarterial chemoembolization in hepatocellular carcinoma

BACKGROUND Conventional transarterial chemoembolization (cTACE) is the current standard treatment for intermediate-stage hepatocellular carcinoma (HCC). Post-embolization syndrome (PES) is complex clinical syndrome that presents as fever, abdominal pain, nausea, and vomiting. Either dexamethasone (DEXA) or N-acetylcysteine (NAC) is used to prevent PES; however, the synergistic effect of their combined therapy for preventing PES and liver decompensation has not been determined. AIM To evaluate the efficacy of DEXA and NAC combination in preventing PES and liver decompensation after cTACE. METHODS Patients with Barcelona Clinic Liver Cancer stage A or B HCC who were scheduled for TACE were prospectively enrolled. All patients were randomly stratified to receive NAC and DEXA or placebo. The dual therapy (NAC + DEXA) group received intravenous administration of 10 mg DEXA every 12 h, NAC 24 h prior to cTACE (150 mg/kg/h for 1 h followed by 12.5 mg/kg/h for 4 h), and a continuous infusion of 6.25 mg/h NAC plus 4 mg DEXA every 12 h for 48 h after cTACE. The placebo group received an infusion of 5% glucose solution until 48 h after procedure. PES was defined by South West Oncology Group toxicity code grading of more than 2 that was calculated using incidence of fever, nausea, vomiting, and pain. RESULTS One-hundred patients were enrolled with 50 patients in each group. Incidence of PES was significantly lower in the NAC + DEXA group compared with in the placebo group (6% vs 80%; P < 0.001). Multivariate analysis showed that the dual treatment is a protective strategic therapy against PES development [odds ratio (OR) = 0.04; 95% confidence interval (CI): 0.01-0.20; P < 0.001). Seven (14%) patients in the placebo group, but none in the NAC + DEXA group, developed post-TACE liver decompensation. A dynamic change in Albumin-Bilirubin score of more than 0.5 point was found to be a risk factor for post-TACE liver decompensation (OR = 42.77; 95%CI: 1.01-1810; P = 0.049). CONCLUSION Intravenous NAC + DEXA administration ameliorated the occurrence of PES event after cTACE in patients with intermediate-stage HCC.

[1]  Sakkarin Chirapongsathorn,et al.  Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient: A randomised, double-blind, placebo-controlled study , 2021, World journal of clinical cases.

[2]  Xin Yang,et al.  Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization , 2021, Journal of Cancer Research and Therapeutics.

[3]  F. A. Moura,et al.  N-Acetylcysteine (NAC): Impacts on Human Health , 2021, Antioxidants.

[4]  R. Vilaichone,et al.  N-Acetylcysteine Prevents Post-embolization Syndrome in Patients with Hepatocellular Carcinoma Following Transarterial Chemoembolization , 2019, Digestive Diseases and Sciences.

[5]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.

[6]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[7]  O. Yokosuka,et al.  A randomized placebo‐controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization , 2018, Hepatology.

[8]  J. Jang,et al.  Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study. , 2017, Journal of vascular and interventional radiology : JVIR.

[9]  J. Hansmann,et al.  Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma. , 2017, Journal of vascular and interventional radiology : JVIR.

[10]  A. Webster,et al.  Probiotics for people with hepatic encephalopathy. , 2017, The Cochrane database of systematic reviews.

[11]  H. Blackburn,et al.  Management of Postembolization Syndrome Following Hepatic Transarterial Chemoembolization for Primary or Metastatic Liver Cancer , 2016, Cancer nursing.

[12]  S. Temin,et al.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2016, Journal of oncology practice / American Society of Clinical Oncology.

[13]  Liyong Pu,et al.  N-acetylcysteine attenuates reactive-oxygen-species-mediated endoplasmic reticulum stress during liver ischemia-reperfusion injury. , 2014, World journal of gastroenterology.

[14]  Fan Wang,et al.  N-Acetylcysteine Attenuates Ischemia-Reperfusion-Induced Apoptosis and Autophagy in Mouse Liver via Regulation of the ROS/JNK/Bcl-2 Pathway , 2014, PloS one.

[15]  J. Chiu,et al.  Protective Effects of N-acetylcysteine and a Prostaglandin E1 Analog, Alprostadil, Against Hepatic Ischemia: Reperfusion Injury in Rats , 2014, Journal of traditional and complementary medicine.

[16]  R. Vilaichone,et al.  Epidemiology and survival of hepatocellular carcinoma in the central region of Thailand. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[17]  D. Hippe,et al.  Postembolization syndrome after hepatic transarterial chemoembolization: effect of prophylactic steroids on postprocedure medication requirements. , 2013, Journal of vascular and interventional radiology : JVIR.

[18]  Seonwoo Kim,et al.  Risk factors and a predictive model for acute hepatic failure after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[19]  E. Garwood,et al.  Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[20]  Z. Abbas,et al.  Adverse events following transarterial chemoembolization for hepatocellular carcinoma and factors predicting such events. , 2013, JPMA. The Journal of the Pakistan Medical Association.

[21]  M. Rudler,et al.  Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. , 2011, The New England journal of medicine.

[22]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Chia-Yang Hsu,et al.  Liver Failure After Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma and Ascites: Incidence, Risk Factors, and Prognostic Prediction , 2011, Journal of clinical gastroenterology.

[24]  William M. Lee,et al.  Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. , 2009, Gastroenterology.

[25]  Shou-Dong Lee,et al.  Fever after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis , 2008, Scandinavian journal of gastroenterology.

[26]  Stephanie Green,et al.  Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria , 1992, Investigational New Drugs.

[27]  R. Parks,et al.  Postchemoembolisation syndrome – tumour necrosis or hepatocyte injury? , 2003, British Journal of Cancer.

[28]  F. Chang,et al.  Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test , 2002, American Journal of Gastroenterology.

[29]  M. Yuen,et al.  A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma , 2002, Cancer.

[30]  D. Leung,et al.  Determinants of postembolization syndrome after hepatic chemoembolization. , 2001, Journal of vascular and interventional radiology : JVIR.

[31]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[32]  J. Critchley,et al.  The treatment of acetaminophen poisoning. , 1983, Annual review of pharmacology and toxicology.

[33]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .